Markus Sieber

2.8k total citations · 1 hit paper
18 papers, 1.8k citations indexed

About

Markus Sieber is a scholar working on Pathology and Forensic Medicine, Neurology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Markus Sieber has authored 18 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pathology and Forensic Medicine, 7 papers in Neurology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Markus Sieber's work include Lymphoma Diagnosis and Treatment (13 papers), CNS Lymphoma Diagnosis and Treatment (7 papers) and Lung Cancer Treatments and Mutations (5 papers). Markus Sieber is often cited by papers focused on Lymphoma Diagnosis and Treatment (13 papers), CNS Lymphoma Diagnosis and Treatment (7 papers) and Lung Cancer Treatments and Mutations (5 papers). Markus Sieber collaborates with scholars based in Germany, Italy and China. Markus Sieber's co-authors include Volker Diehl, Andreas Engert, Andreas Josting, Dirk Hasenclever, Jeremy Franklin, Beate Pfistner, F. Boissevain, Norbert Schmitz, Peter E. Müller and M. Sextro and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Markus Sieber

18 papers receiving 1.8k citations

Hit Papers

Aggressive conventional chemotherapy compared with high-d... 2002 2026 2010 2018 2002 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial
    2002 755 citations Norbert Schmitz, Beate Pfistner et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Markus Sieber Germany 11 1.5k 964 692 454 361 18 1.8k
Woodrow Wells Canada 19 1.3k 0.8× 894 0.9× 548 0.8× 465 1.0× 221 0.6× 43 1.9k
F. Boissevain Germany 7 1.0k 0.7× 655 0.7× 467 0.7× 283 0.6× 235 0.7× 8 1.2k
Monica Balzarotti Italy 23 1.2k 0.8× 699 0.7× 545 0.8× 365 0.8× 402 1.1× 69 1.5k
R S Cox United States 20 1.0k 0.7× 712 0.7× 334 0.5× 747 1.6× 567 1.6× 25 2.1k
Fabrizio Lombardi Italy 13 683 0.4× 749 0.8× 345 0.5× 612 1.3× 428 1.2× 26 1.7k
Barbara Botto Italy 19 1.1k 0.7× 571 0.6× 435 0.6× 288 0.6× 334 0.9× 60 1.3k
Hye Jin Kang South Korea 26 905 0.6× 822 0.9× 256 0.4× 461 1.0× 254 0.7× 120 1.8k
R T Hoppe United States 25 1.2k 0.8× 551 0.6× 356 0.5× 464 1.0× 299 0.8× 47 2.1k
M. Sextro Germany 9 1.3k 0.9× 943 1.0× 567 0.8× 244 0.5× 388 1.1× 10 1.5k
Lorena Appio Italy 4 1.3k 0.8× 885 0.9× 405 0.6× 220 0.5× 404 1.1× 8 1.7k

Countries citing papers authored by Markus Sieber

Since Specialization
Citations

This map shows the geographic impact of Markus Sieber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Sieber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Sieber more than expected).

Fields of papers citing papers by Markus Sieber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Sieber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Sieber. The network helps show where Markus Sieber may publish in the future.

Co-authorship network of co-authors of Markus Sieber

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Sieber. A scholar is included among the top collaborators of Markus Sieber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Sieber. Markus Sieber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Kluska, Sven, Christian Schmiga, Bernd Steinhauser, et al.. (2022). Plating metallization for bifacial i-TOPCon silicon solar cells. AIP conference proceedings. 2487. 20007–20007. 4 indexed citations
2.
Schmiga, Christian, et al.. (2021). Progress of plated metallization for industrial bifacial TOPCon silicon solar cells. Progress in Photovoltaics Research and Applications. 30(6). 615–621. 41 indexed citations
3.
Fox, Stephen, Ulrich Jäger, D. Pysch, et al.. (2019). Adaptation of the industrial PERC solar cell process chain to plated Ni/Cu/Ag front contact metallization. AIP conference proceedings. 2149. 110001–110001. 2 indexed citations
4.
Brand, Andreas A., et al.. (2017). Benefits of different process routes for industrial direct front side plating. Energy Procedia. 124. 823–828. 5 indexed citations
5.
6.
Engert, Andreas, Jeremy Franklin, Hans Theodor Eich, et al.. (2007). Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial. Journal of Clinical Oncology. 25(23). 3495–3502. 162 indexed citations
7.
Josting, Andreas, Lucia Nogová, Jeremy Franklin, et al.. (2005). Salvage Radiotherapy in Patients With Relapsed and Refractory Hodgkin’s Lymphoma: A Retrospective Analysis From the German Hodgkin Lymphoma Study Group. Journal of Clinical Oncology. 23(7). 1522–1529. 86 indexed citations
8.
Eich, Hans Theodor, S. Staar, Axel Goßmann, et al.. (2004). The HD12 Panel of the German Hodgkin Lymphoma Study Group (GHSG). American Journal of Clinical Oncology. 27(3). 279–284. 19 indexed citations
9.
Josting, Andreas, Christian Rudolph, Markus Y. Mapara, et al.. (2004). Cologne High-Dose Sequential Chemotherapy in Relapsed and Refractory Hodgkin Lymphoma - Results of a Large Multicenter Study of the German Hodgkin Lymphoma Study Group (GHSG).. Blood. 104(11). 309–309. 4 indexed citations
10.
11.
Josting, Andreas, S. Wiedenmann, Jeremy Franklin, et al.. (2003). Secondary Myeloid Leukemia and Myelodysplastic Syndromes in Patients Treated for Hodgkin’s Disease: A Report From the German Hodgkin’s Lymphoma Study Group. Journal of Clinical Oncology. 21(18). 3440–3446. 106 indexed citations
12.
13.
Schmitz, Norbert, Beate Pfistner, M. Sextro, et al.. (2002). Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. The Lancet. 359(9323). 2065–2071. 755 indexed citations breakdown →
14.
Rueffer, U., Andreas Josting, Jeremy Franklin, et al.. (2001). Non-Hodgkin’s Lymphoma After Primary Hodgkin’s Disease in the German Hodgkin’s Lymphoma Study Group: Incidence, Treatment, and Prognosis. Journal of Clinical Oncology. 19(7). 2026–2032. 58 indexed citations
15.
Josting, Andreas, U. Rueffer, Jeremy Franklin, et al.. (2000). Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood. 96(4). 1280–1286. 17 indexed citations
16.
Josting, Andreas, U. Rueffer, Jeremy Franklin, et al.. (2000). Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood. 96(4). 1280–1286. 161 indexed citations
17.
Sieber, Markus, et al.. (1999). Hodgkin’s disease – new treatment strategies toward the cure of patients. Cancer Treatment Reviews. 25(3). 169–176. 3 indexed citations
18.
Tesch, Hans, Markus Sieber, & Volker Diehl. (1996). 7b Treatment of intermediate stages. Baillière s Clinical Haematology. 9(3). 543–551. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Woodrow Wells Breakdown of academic impact, for papers by F. Boissevain Breakdown of academic impact, for papers by Monica Balzarotti Breakdown of academic impact, for papers by R S Cox Breakdown of academic impact, for papers by Fabrizio Lombardi Breakdown of academic impact, for papers by Barbara Botto Breakdown of academic impact, for papers by Hye Jin Kang Breakdown of academic impact, for papers by R T Hoppe Breakdown of academic impact, for papers by M. Sextro Breakdown of academic impact, for papers by Lorena Appio
Rankless by CCL
2026